Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis

BACKGROUND: Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, has shown survival benefit in clinical trials of various malignant tumors. Nivolumab-induced pneumonitis is major immune-related adverse event (irAE) that is occasionally serious and life-threatening. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Teppei, Shimizu, Junichi, Hasegawa, Takaaki, Horio, Yoshitsugu, Inaba, Yoshitaka, Hanai, Nobuhiro, Muro, Kei, Hida, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369733/
https://www.ncbi.nlm.nih.gov/pubmed/34399710
http://dx.doi.org/10.1186/s12885-021-08661-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369733/
https://www.ncbi.nlm.nih.gov/pubmed/34399710
http://dx.doi.org/10.1186/s12885-021-08661-3

Ejemplares similares